Form 4: Adaptive Biotechnologies Director Trades Shares

Michelle Renee Griffin, a Director at Adaptive Biotechnologies Corp, reported transactions involving the acquisition and disposition of common stock, executed under a Rule 10b5-1 trading plan.

Summary

• Michelle Renee Griffin, a Director at Adaptive Biotechnologies Corp, engaged in stock transactions on June 25, 2026.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025.
• Griffin acquired 52,084 shares of common stock at an average price of $7.80 per share.
• Subsequently, Griffin disposed of 52,084 shares of common stock at a weighted-average price of $20.18 per share, with individual sales ranging from $20.00 to $20.55.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While the sale of shares by a director can be perceived negatively, the execution under a Rule 10b5-1 plan and the significant profit margin on the sale suggest a pre-planned, potentially opportunistic transaction rather than a signal of distress.

Positives

• The transactions were executed under a Rule 10b5-1 plan, indicating pre-planned and potentially less market-sensitive trading activity.
• The weighted-average sale price of $20.18 is significantly higher than the acquisition price of $7.80, suggesting a profitable execution of the plan.

Negatives

• A significant number of shares were sold by a director, which could be interpreted negatively by the market, despite being pre-planned.

Risks

• The sale of a substantial number of shares by a director, even under a 10b5-1 plan, could signal a lack of confidence in near-term stock performance to some investors.
• The specific details of the sale price range ($20.00 to $20.55) might be scrutinized for optimal timing within the plan.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. It reports past transactions executed under a pre-determined plan.

Management Comments

• The transactions reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 7, 2025.
• The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $20.00 to $20.55, inclusive.
• The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
• The option was fully vested and exercisable.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The execution of a Rule 10b5-1 plan is a common strategy for executives to diversify holdings or manage personal finances while mitigating concerns about insider trading.

Stakeholder Impact

• Shareholders: May interpret the sale of shares by a director with mixed feelings, but the Rule 10b5-1 plan and profit margin may mitigate negative sentiment.
• Management: The pre-planned nature of the trade aligns with good governance practices.
• Regulatory Bodies (SEC): The filing is a routine compliance document.

Next Steps

• The reporting person may provide further details upon request from Adaptive Biotechnologies Corporation, security holders, or the SEC regarding the specific prices of shares sold.

Key Dates

Keywords

Adaptive Biotechnologies Corp, ADPT, Form 4, Insider Trading, Rule 10b5-1, Stock Transaction, Director, Common Stock, Beneficial Ownership